Genticel focuses on curing HPV before it turns into cervical cancer

May 26, 2015 News BioVox

70% of cervical cancer cases are caused by human papillomavirus (HPV) and the traditional HPV vaccines are only useful to prevent, not to treat the infection. Genticel (GTCL) is developing a solution for those who had been previously infected with HPV, and for whom the vaccine would no longer be active, including most adult women carrying the cancerogenic HPV-virus. The company is developing innovative immunotherapies that will work by avoiding cancers that are caused by HPV. They are focusing specifically on preventing cervical cancer by eliminating HPV infection. ProCervix, a therapeutic vaccine currently in the Phase 2 of clinical trials, aims at treating the infection before it turns into cancer. This is a first-in-class immunotherapeutic candidate and a potential blockbuster that could reach about 1 billion euro sales.

The French biotech company Genticel, founded by the Belgian Benedikt Timmerman – former senior director R&D of Novartis Seeds is currently expanding beyond Europe. To obtain licensing revenue from other applications and to increase the visibility for their technology platform on the international market, Genticel has signed a partnership

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts

Subscribe to the BioVox newsletter